JT Group Launches Ploom AURA and EVO Heated Tobacco Sticks in Japan
Article content
Article content
TOKYO — Japan Tobacco Inc. (JT)(TSE:2914) launches Ploom AURA, its next generation heated tobacco device, on May 27, 2025, in Japan, primarily in its Ploom stores and CLUB JT online shop. In parallel, JT Group will roll out EVO, its exclusive and premium heated tobacco sticks (HTS), to complement Ploom AURA and provide adult consumers with the latest and most technologically advanced propositions in the heated tobacco segment. A nationwide launch of Ploom AURA and EVO will start on July 1 in convenience stores and tobacco retail shops. Ploom AURA will roll out globally in the near future.
Article content
The purpose of JT Group's tobacco business is: Creating fulfilling moments. Creating a better future. And with the launch of Ploom AURA in Japan, the world's leading heated tobacco market, JT Group is taking further steps in this direction – bringing to market and adult consumers an innovative and state-of-the-art heated tobacco device, following extensive consumer insights as well as strong research and development.
Article content
'In the Reduced-Risk Products (RRP)* category, we are focusing on providing adult consumers with quality products, rooted in technology, consumer insights, and experience and I truly believe Ploom AURA embraces all these aspects and more. The JT Group will continue to prioritize investments in the heated tobacco sticks segment which maintains the strongest and most consistent growth in the RRP space. Over the course of 2025-2027, we are investing 650 billion yen in RRP, and a significant part of this will be towards Ploom AURA, notably on the launch in Japan and globally,' said Takehiko Tsutsui, Executive Vice President of Reduced-Risk Products.
Article content
Ploom AURA's key focus is on enhancing flavor and the device leverages SMART HEATFLOW heating technology, delivering sensory satisfaction while enabling consumers to enjoy the full essence and richness of tobacco with the absence of combustion and no smell of smoke. The new Heat Select System offers four modes for users to customize their experience in line with their preferences. The device maintains the delicate and organic curves characteristic of Ploom, while evolving into a compact and slim design – combining elegance and practicality.
Article content
EVO is JT Group's global heated tobacco sticks brand, designed to seamlessly enhance Ploom's advanced heating technology and reduced-risk potential. EVO sticks are made from high-quality tobacco leaves, expertly cut and blended to provide a true tobacco taste. An example of meticulous attention to detail, EVO guarantees a satisfying experience with every puff.
Article content
The combination of the cutting-edge technology of Ploom AURA, along with the high-quality EVO heated tobacco sticks, will ensure consumers consistently experience pleasurable heated tobacco moments.
Article content
'The RRP category is reshaping the global tobacco landscape, and I am confident that Ploom AURA and EVO will play key roles in supporting JT Group's ambition of reaching mid-teens share in the HTS segment by 2028,' added Tsutsui.
Article content
*Reduced-Risk Products (RRP): Products with the potential to reduce the risks associated with smoking, such as Heated Tobacco Products, E-Vapor (or vapes), and Oral products like nicotine pouches.
Article content
Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand.
Article content
Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its 'Fulfilling Moments, Enriching Life' purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit https://www.jt.com/.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor and Media Relations Division
Japan Tobacco Inc.
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
This Global REIT Is Riding Asia's AI Wave Straight to the Bank
Equinix (NASDAQ: EQIX) is a powerhouse in digital infrastructure and part of a new class of innovative real estate investment trusts (REITs) laying the groundwork to become the future of real estate investing. It has a strong history of capitalizing on international technology trends that traditional REITs can't match. With a strategic expansion in Indonesia, Equinix is positioning itself for explosive growth, and Wall Street is beginning to take notice. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Why this digital land grab is a big deal Asia is becoming the global epicenter of digital demand, and Indonesia is leading the charge. It's attracting major investments in cloud computing, artificial intelligence (AI), and fintech. By entering the market early and scaling aggressively, Equinix is developing a strategic advantage that will be tough for competitors to match. Indonesia's data center market is projected to grow at a compound annual growth rate (CAGR) of 8% to $3.79 billion through 2030. Cloud giants like Amazon Web Services and Alphabet 's Google Cloud have already announced major investments, but their platforms need physical infrastructure to function. That's what makes Equinix's expansion into Jakarta so strategic. Its newly opened data center is no ordinary server farm. Built to support intensive computing tasks like training and running AI systems, Equinix is creating the critical backbone necessary for digital business growth in Indonesia. This could make Equinix one of tech's most valuable players. The average analyst price target sees Equinix at $1,009, 10% percent higher than it currently sits, a nod to its forward-looking strategy and savvy market expansion. What gives Equinix the edge In addition to its Indonesian assets, Equinix operates 270 data centers across five continents and 35 countries. It has a great track record with its customers, retaining 98% of them. As of Q1 2025, Equinix reported over $2.1 billion in annual adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). This strong combination of global scale, customer loyalty, and reliable earnings is exactly what sets the stage for Equinix's move into Jakarta to be a success. While it's not the highest-dividend REIT, Equinix pays investors 2% annually. But considering its growth trajectory looks more like a tech company than a traditional REIT, that's not too bad. The risks to watch Equinix does face potential pressures though. Their total capital expenditures for 2025 are projected between $3.4 billion and $3.7 billion, with non-recurring expenditures accounting for around 95% of that. This significant investment is partly due to the need to modernize legacy data centers to meet new levels of demand. While these upgrades are essential, they represent a substantial financial commitment that could impact short-term profitability. That said, Equinix ended Q1 2025 with roughly $2.95 billion in cash and cash equivalents and an ample $7.6 billion in total available liquidity. The balance sheet looks sturdy enough to fund expansion without putting shareholders at undue risk. Geopolitical tensions are also on the periphery of investor concerns. As Equinix operates globally, it must navigate regulatory, monetary, and political risks in emerging markets. But these risks appear to be well managed by the company's leadership, and its long-term leases, high renewal rates, and diversified customer base provide stability. It's time to stake your claim in the future of tech real estate Some investors still think REITs are too risky and don't deliver enough value. Those perceptions are often based on underperforming traditional sectors like retail or office space. That's where tech-powered REITs like Equinix come in. Gone are the days when investing in real estate meant buying a piece of something on the ground. Now you're buying into the cloud. Even in comparison to peers like Digital Realty, Equinix still stands out. It has a stronger international footprint, a more premium client base, and better historical uptime. If you're looking for a REIT that combines growth potential with resilience in the digital age, Equinix is arguably a top-tier pick. AI is only as powerful as the infrastructure behind it, and Equinix is building the digital backbone on which the future will run. Jakarta may just be one dot on the map, but it signals Equinix is putting itself at the forefront of the global shift. With recurring revenue, global scale, and a pioneering foothold in high-growth markets like Indonesia, this REIT could quietly become one of the most important tech stocks of the next decade. Investors looking to profit from AI's global expansion without the volatility of pure-play tech stocks may want to give Equinix a closer look. It might not be a flashy choice, but it's in a solid state and could be the smartest upgrade your portfolio makes this year. Should you invest $1,000 in Equinix right now? Before you buy stock in Equinix, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Equinix wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Philippa Main has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Digital Realty Trust, and Equinix. The Motley Fool has a disclosure policy.
Globe and Mail
6 hours ago
- Globe and Mail
'Largest of its Kind' Tesla Stock (NASDAQ:TSLA) Notches Up With New Battery Power Plant in China
While most of us tend to focus on electric vehicle giant Tesla (TSLA) for, well, its electric vehicles, there is one part of Tesla that tends to go oddly underappreciated: its batteries. The things that make the cars go also have a great potential to keep the lights on at our homes. And they may be about to do just that in China, as Tesla will be building a new 'grid-scale battery power plant' therein. The news sent Tesla shares up fractionally in Friday afternoon's trading. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The new plant that Tesla is looking to build represents something of a novel approach to wide-scale power generation. While more and more users are looking to renewables like wind and solar for some part of grid-power operations, even the most fervent supporters of same know that there is a problem there: the sun does not always shine, nor does the wind always blow. So battery plants are being considered more and more as a way to store energy in the good times, to be parceled out to the grid later on. And with Tesla's battery factory in Shanghai already having produced 100 Megapacks—the kind of battery that works at grid-level—in the first quarter alone, Tesla might be able to set up such a plant fairly rapidly. It will be quite a plant, too; reports note that the project will be '…the largest grid-side energy storage project in China,' Tesla representatives noted. Given that one Megapack can offer one megawatt for four hours, that could indeed be a serious power project. Try Before You Buy Want to test-drive a Tesla? Well, you may have an opportunity to do just that thanks to a partnership effort between Tesla and the Electrify Expo, which will allow users to take a Tesla home for the weekend and put it through its paces before returning it. Tesla is just the first such company to go in right now, as Electrify Expo is looking to bring in more carmakers to the deal. Though right now, this is limited to the Los Angeles show only, which starts tomorrow, expansions are likely to follow. Dubbed the 'Electrify Weekender' experience, the event is likely to expand to Chicago, Dallas, New York, San Francisco and Seattle by the end of the year, with the Los Angeles experience serving as a way to work out any kinks in the program. Is Tesla a Buy, Hold or Sell? Turning to Wall Street, analysts have a Hold consensus rating on TSLA stock based on 14 Buys, 12 Holds, and nine Sells assigned in the past three months, as indicated by the graphic below. After a 75.97% rally in its share price over the past year, the average TSLA price target of $286.14 per share implies 11.93% downside risk. See more TSLA analyst ratings Disclosure
Globe and Mail
21 hours ago
- Globe and Mail
Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts
Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection. DelveInsight's latest report, ' Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,' provides a comprehensive overview of the disease's burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation. The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress. Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight's full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients. Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook Some of the key insights of the Ovarian Cancer Market Report: • In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. • Market size is expected to grow with the launch of new ovarian cancer therapies. • The U.S. held the largest share, reaching USD 1.92 billion in 2024. • Total incident ovarian cancer cases in the 7MM were 61K in 2024. • The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. • There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. • In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. • In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. • In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. • Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers. The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection. Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control. As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: Ovarian Cancer Epidemiology The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: • Total incident cases of Ovarian Cancer • Age-specific cases of Ovarian Cancer • Type-Specific Cases of Ovarian Cancer • Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer • Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments. The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction. Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics. Ovarian Cancer Market Outlook The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival. The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment. However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial. The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements. Ovarian Cancer Market Drivers • The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. • Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers • The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. • Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. • Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. • Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies. • Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement. Table of Contents 1. Ovarian Cancer Market Report Introduction 2. Executive Summary for Ovarian Cancer 3. SWOT analysis of Ovarian Cancer 4. Ovarian Cancer Patient Share (%) Overview at a Glance 5. Ovarian Cancer Market Overview at a Glance 6. Ovarian Cancer Disease Background and Overview 7. Ovarian Cancer Epidemiology and Patient Population 8. Country-Specific Patient Population of Ovarian Cancer 9. Ovarian Cancer Current Treatment and Medical Practices 10. Ovarian Cancer Unmet Needs 11. Ovarian Cancer Emerging Therapies 12. Ovarian Cancer Market Outlook 13. Country-Wise Ovarian Cancer Market Analysis (2020–2034) 14. Ovarian Cancer Market Access and Reimbursement of Therapies 15. Ovarian Cancer Market Drivers 16. Ovarian Cancer Market Barriers 17. Ovarian Cancer Appendix 18. Ovarian Cancer Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
